This Funding Opportunity Announcement (FOA) invites applications for the development of innovative research projects in cancer nanotechnology. This initiative, to be known as Innovative Research in Cancer Nanotechnology (IRCN), is an integral component of a broader program - the NCI Alliance for Nanotechnology in Cancer (The Alliance) (http://nano.cancer.gov). IRCN awards are designed to enable multi-disciplinary research and transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should emphasize fundamental understanding of nanomaterial interactions with biological systems and/or mechanisms of their in vivo delivery.
This Funding Opportunity Announcement (FOA), entitled "Toward Translation of Cancer Nanotechnology Interventions (TTNCI)" is to enable the translation of nanotechnology-based cancer interventions relying on next-generation nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. The "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI) awards are designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.
Harnessing principles from chemistry, biology, physics, and engineering, nanotechnology is a multidisciplinary field still in its infancy. Throughout the past decade, nanoparticles and specifically nanoparticle drug delivery systems, have emerged at the forefront of cancer therapies.
Nanotechnology has helped to design and fabricate micro-scale devices, including nanoparticle drug delivery systems able to target tumors and other cancerous tissue. Nanotechnology is also being explored to generate other novel techniques to design biomarkers, immunotherapy, and vaccine development for cancer.
Featuring keynote address by Nobel Laureate Robert Y. Tsien, PhD, this 2.5-day conference will discuss: nanodiagnostics for cancer biomarkers and imaging, nanoparticle toxicity and safety; nanovaccines and nanoimmunotherapeutics; the challenges of targeted delivery in tumors; and nanoparticle-based gene therapy. A discussion of these topics will serve to enhance the translation of research discoveries into improved cancer diagnostic and treatment strategies.
The deadline for poster abstract submission is Wednesday, April 24, 2013.
For complete abstract submission instructions, please send an email to NanoMoscow@nyas.org with "Abstract Information" in the subject line. There is no need to type a message; instructions will be forwarded automatically. Please call 212.298.8632 with any questions.
Call for Early Career Investigator and Underrepresented Minority Travel Fellowships
The deadline for submission of applications is Wednesday, April 24, 2013.
A small number of fellowships will be made available to qualified early career investigators and early career investigators from underrepresented minorities.
This Funding Opportunity Announcement (FOA), entitled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.
The purpose of the U.S.-Russia Bilateral Collaborative Research Partnerships on Cancer program is to stimulate collaborative basic, translational, and clinical research between United States (U.S.)-based researchers and Russian researchers in the areas of cancer biology, prevention, early detection, diagnosis, and treatment as well as the physical and chemical sciences and engineering in cancer biology, nanotechnology, and radiation epidemiology.
The purpose of the U.S.-Russia Bilateral Collaborative Research Partnerships on Cancer program is to stimulate collaborative basic, translational, and clinical research between United States (U.S.)-based researchers and Russian researchers in the areas of cancer biology, prevention, early detection, diagnosis, and treatment as well as the physical and chemical sciences and engineering in cancer biology, nanotechnology, and radiation epidemiology.
The purpose of this Dear Colleague Letter is to advise you about funding opportunities at the National Science Foundation for the research community to propose research projects or workshops that will gather data on the implementation and impacts of recent science policy initiatives including, but not limited to those noted earlier. Especially encouraged are proposals that will:
Develop new, or improve existing, analytical frameworks for evaluating the impacts of federal science policy initiatives;
Explore different agencies' approaches to the implementation of particular policies to examine how variations in approach affect the achievement of intended policy outcomes;
Collect case-study or quantitative data that facilitate identification of best practices in science and innovation policy implementation.